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Abstract
Methylphenidate (MPH) is the most commonly used drug to treat attention deficit/hyperactivity
disorder (ADHD) in children effectively and safely. In spite of its widespread application throughout
one of the most plastic and sensitive phases of brain development, very little is known to date about
its long-term effects on brain structure and function. Hence, this short review updates the influence
of MPH on brain development, since recent human and animal studies suggest that MPH alters the
dopaminergic system with long-term effects beyond the termination of treatment.
Animal studies imply that the effects of MPH may depend on the neural responder system:
Whereas structural and functional parameters are improved by MPH in animals with psychomotor
impairments, they remain unaltered or get worse in healthy controls. While recent behavioural
studies do not fully support such a differential effect of MPH in ADHD, the animal studies certainly
prompt for further investigation of this issue. Furthermore, the abuse of MPH, when (rarely)
intravenously applied, may even impair the maturation of dopaminergic fibres in subcortical brain
areas. This argues for careful clinical assessment and diagnostics of ADHD symptomatology not
only in conjunction with the prescription of MPH. Hence, one should be assured that MPH is only
given to children with clear ADHD symptomatology leading to psychosocial impairment. The
animal data suggest that under these conditions MPH is supportive for brain development and the
related behaviour in children with ADHD.
Background and rationale
Attention deficit/hyperactivity disorder (ADHD) is one of
the most common behavioural disorders in childhood
and may persist into adulthood. According to conserva-
tive estimates, its prevalence is around 3–5% [1]. Includ-
ing subclinical cases with less stringent criteria used the
percentage may rise up to 17% [2]. Although the aetiology
of the disorder is not yet fully understood, a high herita-
bility with vulnerability genes as basis seems to explain
most of the behavioural variance, although obstetric com-
plications and psychosocial adversity may play a role, too
[see recent reviews by [1,3,4]]. In the last years, models of
the neurobiological background of ADHD have become
both more substantial and more complicated by a wealth
of studies which showed that several, rather than one or a
few, neuronal systems are likely to be involved, and that
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tions, attention and delay of reinforcement, i.a., may be
impaired in ADHD patients [rev. in [1,4,5]]. Animal mod-
els have played an important role in gathering this knowl-
edge [rev. in [6,7]].
Methylphenidate (MPH) is the most widely used drug and
the golden standard to treat ADHD [rev. [1,8]]. Its efficacy
and safety has been documented in many studies [9]
However, there is still a gap of knowledge concerning the
influence of MPH on brain development and its long-
term effect on brain structure and function.
Childhood and adolescence are a highly plastic and sensi-
tive period of brain maturation, during which environ-
mental and pharmacological influences exert strong
effects on neural structure and function [see [10,11] for
rev.]. Especially, cognitive, motivational and emotional
functions mature intensively during this period of life.
Such functions are subserved by brain areas that are char-
acterised by a selective innervation of dopamine (DA), i.e.
the prefrontal cortex (PFC), nucleus accumbens (NAc)
and amygdala. The DAergic innervation of these areas
matures late and passes through a phase of drastic ana-
tomical and physiological upheaval during periadoles-
cence [11-13]. Thus, MPH, considered to act as a DA
agonist by blocking the DA and, to a weaker extent,
noradrenaline transporters [14-16] might influence this
process. Although no neurotoxic action of MPH has been
reported so far [17-19], it is quite likely that pharmacolog-
ical interference with the maturing DA system may last-
ingly change the developmental outcome [8,20,21].
Unfortunately, to date, there exist only few studies inves-
tigating the long-term plastic neuronal effects of MPH. But
it is known that neurotransmitters and their agonists exert
a strong morphogenetic influence on single neurons and
nervous tissues [22-26], and even small environmental
events can lastingly shape the brain if applied over a
longer period [27-31](Lehmann, Grund et al., unpub-
lished observations). Indeed, some studies have already
shown that early treatment with clinical doses of MPH
persistently changes DAergic parameters in rodents
[20,32-34]. We therefore dedicate this mini-review to the
behavioural and neurobiological long-term effects of
MPH in humans and experimental animals.
Dopamine function and dysfunction in ADHD
As an indirect DA agonist, MPH presumably enhances
DAergic transmission in the very same brain areas that
play such an important role for cognition and emotion,
and two of them – the PFC and the NAc – are considered
to be principally involved in the aetiology of ADHD.
Genetic research and in vivo imaging observations have
put the focus on DA dysfunction in ADHD by document-
ing increased dopa decarboxylase activity in the midbrain
[35], decreased sensitivity of the DA receptor type 4 and
increased density of the DA transporter (DAT) in the stria-
tum/NAc [36-42]. In the PFC, there is a reduced DA stor-
age in ADHD patients [43], and it has been shown that
MPH increases the extracellular DA concentration in the
PFC [44,45]. This cannot, however, be achieved in a
straightforward way, since neither DAT nor D2 receptors
are present in detectable or even sufficient amounts in the
PFC [46-49]. Instead, it has been shown that MPH blocks
not only the DAT, but also the noradrenaline transporter
(NAT) [15], and that DA is cleared by the NAT in the PFC
[50]. Since DA serves as a switch between cortical input
into the PFC (with low DA transmission) and thalamic
input (with high DA transmission, fig. 1), the functional
consequence will be a behaviour that is more driven by
information coming from non-cortical regions, rather
than by intrinsic cortical information [109,110].
There is an ongoing debate on the DAergic pathology of
the NAc in ADHD (fig. 2). Both a lack and an excess of DA
Neuronal connections of Prefrontal CortexFig re 1
Neuronal connections of Prefrontal Cortex. Dopamine 
(DA) fibres arising in the ventral tegmental area terminate on 
GABAergic interneurons and glutamatergic pyramidal cells in 
the PFC. DA serves as a switch between cortical (with low 
DA transmission) and thalamic input (with high DA transmis-
sion) [117,118]. +-signs signify an excitation and – signs sig-
nify an inhibition. IV, V and VI = layer IV, V and VI; P = 
pyramidal cell; PFC = prefrontal cortex; TH = thalamus; UC 
= u-shaped cortical connections; VTA = ventral tegmental 
area.Page 2 of 14
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imental evidence. The higher DAT density in ADHD
patients, which should improve DA clearance from the
synaptic cleft [28-30], the action of MPH as an indirect DA
agonist, and imaging data demonstrating increased extra-
cellular DA concentrations in the striata of healthy con-
trols after MPH treatment [51], all argue for a reduced
striatal DAergic transmission in ADHD. The opposing
view assuming an accumbal DA hyperfunction in ADHD,
in contrast, maintains that DAT density may be regarded
as a measure of DA fibre density [31-34]. It further pro-
poses the fact that there are two different kinds of DA
transmission in the striatum [52]: Firing of DA neurons
leads to a phasic release of DA in relatively high concen-
trations. The transmitter is cleared by the very effective
DAT, so only very low concentrations of DA remain in the
extracellular space. This tonic transmission is, however,
still strong enough to activate autosynaptic D2 receptors
which inhibit phasic DA firing. By blocking the DAT,
MPH may increase the tonic extracellular DA concentra-
tions and thus decrease the phasic transmission [53]. The
observation that DA antagonists increase the positive
effect of MPH on motor behaviour [54,55], but prevent its
enhancement of cognitive capacities [56], further sup-
ports this hypothesis. In this view, the two impairments in
PFC and NAc are probably even causally related, since
alterations of DA metabolism in the PFC reciprocally
change the DA activity in the striatum [57-62].
The DA projection to the amygdala matures in close coor-
dination with that of the PFC, such that DA hypoinnerva-
tion of the PFC goes along with DA hyperinnervation of
the amygdala (and entorhinal cortex) after early trauma
[63]. Furthermore, the amygdala receives a strong projec-
tion from the PFC [64] which serves to put reflexive fear
reactions under cognitive control (fig. 3) [65-67].
Although these neuronal effects after early trauma in ger-
bils should be considered only as a partial model of
ADHD, it might be fruitful for further reasoning to
remember that a high frequency of associated emotional
problems has been reported in ADHD patients [9], but
Neuronal connections of Nucleus AccumbensFig re 2
Neuronal connections of Nucleus Accumbens. Gluta-
matergic afferences from the prefrontal cortex, hippocampus 
and amygdala terminate on GABAergic medium spiny neu-
rons and are modulated pre- and postsynaptically by 
dopamine. The glutamatergic input from the hippocampus 
and the amygdala drives the medium spiny neurons into a 
depolarized state and the input from the prefrontal cortex is 
capable of triggering action potentials [119]. AMY = amy-
gdala; HC = hippocampus; PFC = prefrontal cortex; NAc = 
nucleus accumbens; VTA = ventral tegmental area.
Neuronal connections of AmygdalaFig re 3
Neuronal connections of Amygdala. Glutamatergic 
afferents from the prefrontal cortex (PFC) contact GABAer-
gic interneurons in the basolateral amygdala, which then 
inhibit the firing of pyramidal cells, while afferents from sen-
sory cortices terminate mainly on glutamatergic pyramidal 
cells. The PFC input is suppressed presynaptically, whereas 
the sensory cortical input is enhanced postsynaptically by DA 
[67,120]. AMY = amygdala; P = pyramidal cell; PFC = pre-
frontal cortex; VTA = ventral tegmental area, SC = sensory 
cortices.Page 3 of 14
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and its modifications by MPH in these cases.
Therapeutic effects of methylphenidate
The most commonly used genetic rodent model of ADHD
is the spontaneously hypertensive rat (SHR) [rev. in [68-
70]]. In this model, reduced DA transmission was found
in the PFC and striatum [7,71]. In the NAc, D1 receptor
densities were increased, while D2 receptor densities were
lowered [32,72-74] – which is in line with the current con-
ception of ADHD in humans as outlined above. Oral
MPH treatment for two weeks significantly changes these
receptor densities to normal values [32,74]. Accordingly,
Russell and colleagues [7] reported that MPH treatment
alleviates ADHD-like symptoms in this rodent model.
In our lab, we studied the long-term plastic effects of MPH
in a model of hyperkinetic behaviour that bears some
resemblance to ADHD, i.e. gerbils after an early traumatic
experience [33,34]. Early trauma is not a typical, but a
possible factor in the aetiology of ADHD [75]. A single
high dose of methamphetamine (MA), administered on
postnatal day 14, causes a syndrome in young-adult ger-
bils that is characterised by hyperactivity, increased fear-
fulness and impaired PFC function in both working
memory and extinction [76,77]. Neuroanatomically, this
Oral application of Methylphenidate (MPH) – Effects on Prefrontal Cortex (PFC)Figure 4
Oral application of Methylphenidate (MPH) – Effects on Prefrontal Cortex (PFC). Dopamine (DA) fibre density + 
S.E.M. is presented in lamina I, III and V of the PFC. Three effects are noteworthy. First, methamphetamine (MA) (= MA-H2O) 
impaired the maturation of DA fibres in layer V, as had been shown before [78]. Second, MPH treatment for 30 days returned 
DA fibre densities to control values in MA-traumatised (= MA-MPH) animals. In control animals, in contrast, MPH (= saline-
MPH) did not change the DA fibre densities, or even rather reduced them. Third, application of water (= saline-H2O), i.e., pure 
handling, was highly effective in increasing the DA fibre densities in all layers. As isolated rearing by itself allows only for a sup-
pressed maturation of DA fibres, this latter finding suggests that handling is a beneficial, "therapeutic" intervention (Lehmann, 
Grund et al., unpublished observations). For biostatistics two-way ANOVA with post-hoc contrast analysis among treated 
groups or pairwise comparisons with t-tests for untreated controls vs. treated groups were used for each lamina; significance 
values: *p < 0,05, **p < 0,01, ***p < 0,001.Page 4 of 14
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Oral application of Methylphenidate – effects on Ventral StriatumFigure 5
Oral application of Methylphenidate – effects on Ventral Striatum. Dopamine (DA) fibre density + S.E.M. is pre-
sented in the nucleus accumbens shell, core and olfactory tubercle. In the nucleus accumbens, neither handling nor MPH 
exerted any effects on the DA innervation of the ventral striatum. For abbreviations, see fig. 4. Biostatistics: ANOVA with 
repeated measures and t-tests (see fig. 4).
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Oral application of Methylphenidate – effects on AmygdalaFigure 6
Oral application of Methylphenidate – effects on Amygdala. Dopamine (DA) fibre density + S.E.M. is presented in the 
basolateral, lateral and medial central amygdala. In the basolateral amygdala, results correspond to those in the PFC: Handling-
induced rise in DA fibre density, MA-induced decrease and MPH-induced recovery. The DA innervation of the central amy-
gdala did not react to MPH, but was lowered in the medial part by handling. For abbreviations, see fig. 4. Biostatistics: ANOVA 
with repeated measures and t-tests (see fig. 4); significance values: *p < 0,05, **p < 0,01.
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increased entorhinal and amygdalar DA fibre densities
[63,78,79]. Other neuromodulators like serotonin and
acetylcholine adapt to this changed situation by altering
their innervation densities, too [80,81].
In this animal model of early traumatic experience, we
applied MPH both orally and (see below) intraperito-
neally (i.p.) during adolescence (PD30–60) to isolation-
reared, MA intoxicated gerbils. While the oral application
was designed to match human medication, the i.p. appli-
cation was meant to study the effects of MPH abuse. Two
control groups were taken, one being left undisturbed,
whereas the other received water. DA fibres were stained
immunohistochemically, and their densities assessed by
computerised image analysis in the PFC (anterior cingu-
late, prelimbic and infralimbic), ventral striatum (NAc
core and shell, olfactory tubercle) and the central (lateral
and medial) and basolateral amygdalar subnuclei. Addi-
tionally, cell proliferation rates in the hippocampal den-
tate gyrus were counted as a measure of long-term
memory plasticity.
In the PFC, three effects are noteworthy (fig. 4). First, MA
(= MA-H2O) impaired the maturation of DA fibres in the
prelimbic cortex, as had been shown before [78]. Second,
MPH treatment for 30 days returned DA fibre densities to
control values in MA-traumatised (= MA-MPH) animals.
In control animals, in contrast, MPH (= saline-MPH) did
not change the DA fibre densities, or even rather reduced
them. Third, application of water (= saline-H2O), i.e.,
pure handling, was highly effective in increasing the DA
fibre densities in both the anterior cingulate and prelim-
bic cortices. As isolated rearing by itself allows only for a
suppressed maturation of DA fibres, this latter finding
suggests that handling is a beneficial, "therapeutic" inter-
vention (Lehmann, Grund et al., unpublished observa-
tions).
In contrast to the PFC results, neither handling nor MPH
exerted any effects on the DA innervation of the ventral
striatum (fig. 5). If anything, there seemed to be a slight,
but non-significant rise in fibre densities after MPH treat-
ment in MA-intoxicated animals. In the basolateral amy-
gdala (fig. 6), results correspond to those in the PFC:
Handling-induced rise in DA fibre density, MA-induced
decrease and MPH-induced recovery. The DA innervation
of the central amygdala did not react to MPH, but was
lowered in the medial part by handling.
That MPH restores the DA innervation of the gerbil PFC
that was lesioned by MA indicates a beneficial effect of
MPH treatment, which is confirmed by studies demon-
strating improved attention and working memory in ani-
mals treated with MPH [82,83]. Since no impairments in
long-term memory have been found in ADHD patients
[84], and MPH, consequently, does not seem to influence
this neuropsychological function [85-88], it is not surpris-
ing that we did not detect any effect of MPH on the hip-
pocampal cell proliferation (data not shown). As
numerous endo- and exogenous substances, including
many psychopharmacological drugs, have been demon-
strated to alter the dentate mitotic activity [rev. in [89],
this result rather underlines the specificity of MPH as an
enhancer of PFC/NAc-based function.
Concerning the clinical use of MPH, the reported findings
in animals suggest that disturbed brain systems may react
differently to the drug than those with a normal develop-
ment. However, empirical evidence in humans with and
without ADHD shows that the situation is rather complex.
At the clinical behavioural level, Rapoport and Inoff-Ger-
main [90] reported in an update that stimulants appear to
have basically similar behavioural effects in normal and
in hyperactive children, as had first been shown for dex-
troamphetamine [91,92]. But taking the neuropsycholog-
ical level of behaviour into account, a different picture can
be seen: MPH improved response inhibition in the
healthy and ADHD group in one task and only in ADHD
children in the other task [93]. Similarly, Elliott et al. [94]
found that MPH influenced performance in two conflict-
ing ways in healthy young adults; enhancing executive
aspects of spatial function in novel tasks but impairing
previously established performance. Further, beneficial
effects of MPH on working memory seem to be greatest in
the subjects with lower baseline working memory capacity
[95]. Finally, looking at neural substrates of motor and
cognitive control in fMRI, MPH seems to affect striatal
activation differently in ADHD (positive) than in healthy
(negative) children while increased frontal activation was
seen in both groups [93]. A neurophysiological study with
transcranial magnetic stimulation could demonstrate
opposite effects of MPH on neuronal excitability in chil-
dren with ADHD versus healthy controls [96].
In conclusion, a transfer from animal data on MPH to
MPH treatment in human ADHD is always limited.
Although the neuronal systems of ADHD patients work
differently than those of healthy controls, some perform-
ing/behavioural output after MPH looks similar. How-
ever, distinct rather than unitary patterns of functional
abnormality in ADHD have to be taken into considera-
tion and a differential treatment approach seems to be
adequate, which might work best for patients with an une-
quivocal ADHD symptomatology and psychosocial
impairment, although only strong levels of response may
be predicted by a few baseline characteristics (e.g. consid-
erable inattentiveness [97]).Page 7 of 14
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Intraperitoneal application of Methylphenidate – Ventral StriatumFigur  7
Intraperitoneal application of Methylphenidate – Ventral Striatum. Dopamine (DA) fibre density + S.E.M. is pre-
sented in the nucleus accumbens (NAc) shell, core and olfactory tubercle. I.p. MPH only had an effect in control animals, and 
only the lower, clinical dose (= saline-MPH 5) was effective in reducing the DA innervation density in both subterritories of the 
NAc. The DA innervation was unaltered by the higher dose of MPH (= saline-MPH 50), and even significantly denser than after 
treatment with the clinical dose in the NAc core. For abbreviations, see fig. 4. Biostatistics: Two-way ANOVA with repeated 
measures; significance values: *p < 0,05, **p < 0,01.
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Intraperitoneal application of Methylphenidate – AmygdalaFigur  8
Intraperitoneal application of Methylphenidate – Amygdala. Dopamine (DA) fibre density + S.E.M. is presented in the 
lateral, basolateral, lateral and medial central amygdala. Similar, albeit not quite significant effects were observed in the lateral, 
basolateral and medial part of the central amygdala. Only in the lateral part of the central amygdala did the high dose of MPH (= 
MA-MPH 50) i.p. increase the DA fibre density in MA-intoxicated animals. For abbreviations, see fig. 4. Biostatistics: Two-way 
ANOVA with repeated measures; significance values: *p < 0,05, **p < 0,01.
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notion that psychomotor impaired individuals and
healthy controls show indeed opposite responses to
ADHD (fig. 4). This finding is further corroborated by
behavioural animal studies which show that MPH treat-
ment improves attention in bad performers, but has no
effect on normal controls in the 5-choice serial reaction
time task [82]. Furthermore, MPH did not induce locomo-
tor sensitization in SHRs [98], but caused both locomotor
sensitization and cross-sensitization to amphetamine in
normal rat strains [98,99]. More studies will be needed to
clarify this issue.
Although we did not find altered DA fibre densities in the
NAc, MPH treatment indeed exerts significant and long-
lasting functional effects in the NAc: In contrast to other
stimulant drugs, MPH does not sensitise the rewarding
effects of other drugs, but instead reduces the risk for sub-
stance abuse both in rats [100,101] and humans [[102],
rev. in [103]], although there are conflicting results in rats
[104]. Since clinical doses do not increase extracellular
accumbal DA levels, but change noradrenaline concentra-
tions [105-107], it seems likely that this beneficial effect is
not mediated primarily via the DA system. Nevertheless,
as mentioned above, accumbal DA receptor densities are
altered by MPH treatment [32]. Furthermore, MPH treat-
ment during adolescence lastingly decreases the DAT con-
centration in the NAc, while leaving the densities of the
serotonin and noradrenaline receptors untouched [20].
Thus, the alterations occuring in the NAc are obviously
rather of a physiological kind, possible due to the much
earlier maturation of the accumbal than the prefrontal DA
innervation [12,108,109].
The increased DA fibre density found in the basolateral
amygdala of MPH-treated MA-intoxicated gerbils is a first
hint that MPH affects neural systems beyond PFC and
NAc. It corresponds to further results from the above men-
tioned behavioural study showing that MPH-treated rats
respond stronger to aversive situations and show more
anxiety-like behaviour [101].
Methylphenidate as a psychostimulant drug of abuse
Orally taken, MPH has no abuse potential because of its
slow increase of the plasma level, while a "high" (with the
associated risk of drug abuse) can be elicited by i.v. appli-
cation [110]. Hence, when abused, MPH is usually
applied intravenously [103,111]. This route of applica-
tion dodges the pronounced hepatic first-pass metabo-
lism that MPH is subjected to after oral consumption
[112]. In consequence, higher plasma concentrations are
reached about six times faster and with a much shorter
half life [113], and extracellular DA concentrations in the
NAc are higher [106]. Although the abuse of MPH is
rather rare, it seems to be important to investigate if the
potential long-term plastic effect of this kind of applica-
tion differs from that of oral application.
To our knowledge, there is as yet no other animal study on
the long-term effects of intraperitoneally or intravenously
applied MPH except for one from our lab that we briefly
summarise here [33,34]. We studied the plastic long-term
effects of i.p. MPH on the DA innervation in the above
described model. Two different concentrations of MPH
were investigated, one (5 mg/kg) in the clinical range, the
other (50 mg/kg) clearly beyond it. DA fibre densities
were measured in the ventral striatum and amygdala. Data
for the PFC could not be obtained out of technical prob-
lems, but previous experience with our model would sug-
gest that DA fibres in the PFC react in a similar way to
those in the NAc.
Surprisingly, i.p. MPH only had an effect in control ani-
mals, and only the lower, clinical dose (= saline-MPH 5)
was effective in reducing the DA innervation density in
both subterritories of the NAc (fig. 7). The DA innervation
was unaltered by the higher dose of MPH (= saline-MPH
50), and even significantly denser than after treatment
with the clinical dose in the NAc core. Similar, albeit not
quite significant effects were observed in the lateral, baso-
lateral and medial part of the central amygdala (fig. 8).
Only in the lateral part of the central amygdala did the
high dose of MPH (= MA-MPH 50) i.p. increase the DA
fibre density in MA-intoxicated animals.
Our results demonstrate that by i.p. application, MPH can
indeed impair the postnatal maturation of DA fibres in
the ventral striatum in a similar way as a single high dose
of MA [79,109]. We can offer no explanation why the
higher dose of MPH has no detectable effects in the ana-
tomical dimension. It has been shown, however, that
already a single dose of MPH in that range (30 mg/kg)
sensitises rats for the locomotor-effect of amphetamine
[105], thus making them more prone for a drug addiction.
An up-regulation of the cAMP pathway in the NAc medi-
ated via D2 receptors has been implicated in this kind of
sensitization [114], so here again changes may rather be
intracellular and physiological than anatomical.
Conclusion
MPH is an indispensable drug that beautifully fits the
pharmacological demands to regulate DA dysfunctions in
ADHD. In patients with this disorder, MPH simultane-
ously compensates a prefrontal DA hypofunction and
probably restrains an accumbal DA hyperfunction in the
long run. Animal studies suggest that this effect is sup-
ported in the PFC by enhancing the maturation of DA
fibres [33,34], whereas adaptations of pre- and postsynap-
tic receptor densities are elicited in the NAc. Both clinical
and preclinical studies converge to confirm that in sub-Page 10 of 14
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impairments, MPH has long-term beneficial effects in sev-
eral respects, e.g. by reducing the core symptoms of
ADHD as well as the risk for substance abuse [e.g.
[102,103,115]. A certain reservation must be deduced
from the observation that both the DA innervation and
the behavioural function of the amygdala are altered by
MPH, making animals more fearful and sensitive to stress-
ful stimuli [33,101]. However, since the behavioural
study used normal rats, further investigations are needed
to check whether adverse emotional effects are also
evoked by MPH in animal models of ADHD.
This latter consideration directly leads us to one of two
important caveats concerning the use of MPH: Behav-
ioural studies show that MPH is ineffective in rodents
without attentional impairments [82], as far as attention
is concerned. In contrast, MPH elicits locomotor sensitiza-
tion in non-hyperactive rat strains, whereas it has no such
effect in SHRs [98]. The assessment of DA fibre densities
confirms that these are only improved in previously trau-
matised animals, but unchanged or possibly even reduced
in healthy controls [33,34]. Transformed to a clinical per-
spective, this might suggest that physicians are possibly
dealing with (at least partly) quantitatively and/or quali-
tatively different responder systems when treating the
brains of children with or without ADHD [see also
[7,116]]. This perspective is supported by different effects
of MPH on neuronal excitability (measured with transcra-
nial magnetic stimulation) in healthy persons compared
with ADHD patients [96]. However, as discussed above,
there are also partly conflicting data [90-95], making it
impossible to arrive at a firm conclusion so far.
Finally, being a psychostimulant, MPH has unfortunately
also been discovered by some as a drug of abuse that is
intravenously applied. First results on the long-term effect
of such abuse in animals has shown equivocal results,
with negative effects similar to methamphetamine in low
but no effect with high doses of MPH [33,79]. It remains
to be checked whether it may even be neurotoxic under
such conditions. Nevertheless, the wealth of human and
animal information on MPH shows the great value of the
drug which has to be handled with care to use it in the
right way.
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